ZA8681B - 1,2-dialkoxy-omega-trialkylammonium cationic surfactants - Google Patents
1,2-dialkoxy-omega-trialkylammonium cationic surfactantsInfo
- Publication number
- ZA8681B ZA8681B ZA8681A ZA8681A ZA8681B ZA 8681 B ZA8681 B ZA 8681B ZA 8681 A ZA8681 A ZA 8681A ZA 8681 A ZA8681 A ZA 8681A ZA 8681 B ZA8681 B ZA 8681B
- Authority
- ZA
- South Africa
- Prior art keywords
- dialkoxy
- omega
- cationic surfactants
- trialkylammonium cationic
- carbons
- Prior art date
Links
- 239000003093 cationic surfactant Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- -1 piperidino, pyrrolidino Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Detergent Compositions (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68940785A | 1985-01-07 | 1985-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA8681B true ZA8681B (en) | 1987-08-26 |
Family
ID=24768317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA8681A ZA8681B (en) | 1985-01-07 | 1986-01-06 | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0187702B1 (ja) |
| JP (2) | JPH0662517B2 (ja) |
| AT (1) | ATE50983T1 (ja) |
| AU (1) | AU594654B2 (ja) |
| CA (1) | CA1288774C (ja) |
| DE (1) | DE3669503D1 (ja) |
| NZ (1) | NZ214716A (ja) |
| ZA (1) | ZA8681B (ja) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| SE464448B (sv) * | 1985-04-04 | 1991-04-29 | Int Genetic Sciences | Fusogen fosfolipidvesikel innehaallande ett kvaternaert ammoniumhydroxidsalt i membranet samt ett foerfarande foer dess framstaellning |
| US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| DE4013632A1 (de) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| DK0550463T3 (da) * | 1990-09-06 | 1996-11-04 | Johnson & Son Inc S C | Fremgangsmåde til stabilisering af liposomer samt sammensætninger indeholdende dem |
| GB2250998A (en) * | 1990-12-21 | 1992-06-24 | Unilever Plc | Cosmetic cleansing composition |
| JP3594962B2 (ja) * | 1992-04-03 | 2004-12-02 | コスモフェルム ベースローテン フェンノートシャップ | アミノアルコールの選択的n‐アシル化 |
| US5674908A (en) * | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
| JPH07308570A (ja) * | 1994-05-16 | 1995-11-28 | Hirotaka Hirata | 界面活性物質を含む分子複合体 |
| CA2237316C (en) * | 1995-11-30 | 2012-06-26 | Vical Incorporated | Complex cationic lipids |
| DE19605175A1 (de) | 1996-02-13 | 1997-08-14 | Sourovoi Andrej Dr | Lipidverbindungen und deren Verwendung |
| ATE395904T1 (de) | 1996-09-13 | 2008-06-15 | Lipoxen Technologies Ltd | Liposome |
| US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| AU5366099A (en) | 1998-08-20 | 2000-03-14 | Connaught Laboratories Limited | Nucleic acid molecules encoding inclusion membrane protein of (chlamydia) |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| EP1829856A3 (en) | 1998-11-12 | 2009-02-25 | Invitrogen Corporation | Transfection reagents |
| AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
| ATE346925T1 (de) | 2000-05-10 | 2006-12-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
| US7432371B2 (en) | 2002-02-07 | 2008-10-07 | Covalent Partners, Llc | Nanofilm and membrane compositions |
| EP1356820A1 (en) | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA vaccine combined with an inducer of tumor cell apoptosis |
| JP2006273341A (ja) * | 2005-03-28 | 2006-10-12 | Toppan Printing Co Ltd | 乾燥能力インジケーター機能付蓋 |
| JP5072275B2 (ja) | 2006-07-03 | 2012-11-14 | テルモ株式会社 | 閉鎖小胞の分離方法、製剤の製造方法および評価方法 |
| EP2069378B1 (en) | 2006-10-06 | 2016-10-05 | The Scripps Research Institute | Dna composition for eliciting an immune response against tumor-associated macrophages |
| JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
| WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| CA2756070C (en) | 2009-03-27 | 2019-08-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Kanamycin antisense nucleic acid for the treatment of cancer |
| WO2011064790A1 (en) * | 2009-11-30 | 2011-06-03 | Avra Laboratories Pvt. Ltd | A novel process for making aliskiren, its novel intermediates and certain novel compounds |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| CA2792956C (en) | 2010-03-17 | 2021-11-16 | Socpra - Sciences Et Genie, S.E.C. | Bacterial vaccine components from staphylococcus aureus and uses thereof |
| US9408914B2 (en) | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| JP5902617B2 (ja) | 2010-04-28 | 2016-04-13 | 協和発酵キリン株式会社 | カチオン性脂質 |
| US8895017B2 (en) | 2010-06-07 | 2014-11-25 | Pfizer Inc. | HER-2 peptides and vaccines |
| JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
| AU2012353463B2 (en) | 2011-12-12 | 2017-08-24 | Kyowa Hakko Kirin Co., Ltd. | Lipid nanoparticles containing combinations of cationic lipids |
| JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| US9913907B2 (en) | 2012-07-16 | 2018-03-13 | Kyowa Hakko Kirin Co., Ltd. | RNAi pharmaceutical composition for suppressing expression of KRAS gene |
| WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| TW201726614A (zh) | 2015-12-25 | 2017-08-01 | Kyowa Hakko Kirin Co Ltd | 作為陽離子性脂質之化合物 |
| ES2811523T3 (es) | 2016-01-19 | 2021-03-12 | Pfizer | Vacunas contra el cáncer |
| BR112019007796A2 (pt) | 2016-10-21 | 2019-09-03 | Socpra Sciences Et Genie Sec | construção de vacina e seus usos contra infecções causadas por staphylococcus |
| EP3538546B1 (en) | 2016-11-14 | 2025-01-08 | Novartis AG | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
| IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
| IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
| WO2022047176A2 (en) | 2020-08-28 | 2022-03-03 | University Of Houston System | Single-chain coronavirus viral membrane protein complexes |
| US20220185852A1 (en) | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
| CN116003271B (zh) * | 2022-12-13 | 2025-08-29 | 江西品信药业股份有限公司 | 一种季铵类脂质的合成方法 |
| WO2024200831A1 (en) | 2023-03-30 | 2024-10-03 | Vivadju | Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3567729A (en) * | 1968-01-12 | 1971-03-02 | Swift & Co | Diquaternary ammonium halides |
-
1986
- 1986-01-06 CA CA000499079A patent/CA1288774C/en not_active Expired - Lifetime
- 1986-01-06 ZA ZA8681A patent/ZA8681B/xx unknown
- 1986-01-06 DE DE8686300037T patent/DE3669503D1/de not_active Expired - Lifetime
- 1986-01-06 EP EP86300037A patent/EP0187702B1/en not_active Expired - Lifetime
- 1986-01-06 AT AT86300037T patent/ATE50983T1/de not_active IP Right Cessation
- 1986-01-06 AU AU51853/86A patent/AU594654B2/en not_active Expired
- 1986-01-06 JP JP61001235A patent/JPH0662517B2/ja not_active Expired - Lifetime
- 1986-01-06 NZ NZ214716A patent/NZ214716A/xx unknown
-
1994
- 1994-02-23 JP JP6025546A patent/JP2546623B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5185386A (en) | 1986-07-17 |
| ATE50983T1 (de) | 1990-03-15 |
| JP2546623B2 (ja) | 1996-10-23 |
| JPH0770011A (ja) | 1995-03-14 |
| JPS61161246A (ja) | 1986-07-21 |
| JPH0662517B2 (ja) | 1994-08-17 |
| CA1288774C (en) | 1991-09-10 |
| EP0187702B1 (en) | 1990-03-14 |
| NZ214716A (en) | 1989-04-26 |
| DE3669503D1 (de) | 1990-04-19 |
| AU594654B2 (en) | 1990-03-15 |
| EP0187702A1 (en) | 1986-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ214716A (en) | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants | |
| HU906029D0 (en) | Process for the preparation of pleuromuthylyne derivatives | |
| AU586691B2 (en) | Diamino-androstane derivatives, process for their preparation and pharmaceutical compositions containing them | |
| EP0132845A3 (en) | Novel 1,8-naphthyridine derivatives, and process for preparation thereof | |
| AU2722288A (en) | Certain 3-substituted 2-alkyl benzofuran derivatives | |
| HUT59693A (en) | Process for producing morpholinyl derivatives of doxorubicin and pharmaceutical compositions containing them | |
| ATE96446T1 (de) | Estramustin-ester. | |
| AU576926B2 (en) | Tetrazole derivatives | |
| AU631671B2 (en) | 2-(2-vinylpyrrolidinylthio)carbapenem derivatives | |
| DE3864336D1 (en) | Aromatische thioaether. | |
| IL78625A0 (en) | Furanone derivatives and their preparation | |
| IL106934A0 (en) | Heteroarenylpiperazines,a process for their preparation and their use as medicaments |